These results validated the use of molecular ultrasonography for in vivo detection and quantification of VEGFR2 expression in breast cancer models and for the evaluation and longitudinal monitoring of new antiangiogenic drug efficacy [24]. This evidence concerns the gene KDR and breast carcinoma.